Insider Trading March 11, 2026

Natera CFO Sells $160,244 Worth of Shares as Stock Trades Below Transaction Price

Quarterly beat and diverging analyst targets accompany insider sale and RSU vesting

By Avery Klein NTRA
Natera CFO Sells $160,244 Worth of Shares as Stock Trades Below Transaction Price
NTRA

Natera Inc.'s Chief Financial Officer Michael Burkes Brophy sold 785 shares on March 10, 2026, for roughly $160,244, and received 1,968 fully vested restricted stock units a day earlier. The stock has risen 36% over the past year but currently trades below Brophy's sale price. The company reported stronger-than-expected Q4 2025 revenue, while analysts maintain differing price targets and ratings.

Key Points

  • Company CFO Michael Burkes Brophy sold 785 shares on March 10, 2026, for about $160,244 and received 1,968 vested RSU shares on March 9, 2026.
  • Natera reported Q4 2025 revenue of $666 million, beating the $590.72 million estimate and showing year-over-year growth.
  • Analysts differ on valuation - Canaccord Genuity maintained a $285 target and Buy rating, while Morgan Stanley lowered its target to $250 but kept an Overweight rating.

Chief Financial Officer Michael Burkes Brophy reduced his stake in Natera Inc. (NASDAQ: NTRA) by selling 785 shares on March 10, 2026, at a per-share price of $204.1327, yielding proceeds of approximately $160,244.

The disposition occurred after a one-day transaction on March 9, 2026, when Brophy was issued 1,968 shares of common stock tied to Restricted Stock Units that were fully vested at issuance. Following these two transactions, Brophy directly holds 63,354 shares of Natera.

Market context around the sale shows the stock has produced a 36% return over the past 12 months. Despite that gain, shares are trading beneath Brophy’s sale price; the current quote is $196.61.


Separately, Natera reported its fourth-quarter 2025 financial results that surpassed revenue expectations. The company posted revenue of $666 million versus consensus estimates of $590.72 million, representing notable year-over-year growth for the period.

Analysts have reacted to the quarter with differing valuations and stances. Canaccord Genuity reiterated a Buy rating on the stock and maintained a $285 price target, citing robust test volume growth across Natera’s business segments. Morgan Stanley, while preserving an Overweight rating, trimmed its price target to $250 following adjustments to its model and noted the change reflects a discounted cash flow analysis underpinning its valuation.


The insider sale, the RSU issuance and the recent earnings beat together present a mixed picture: management pocketed proceeds from a sale at a price above the current market level, while the company delivered stronger-than-expected top-line performance that prompted divergent price targets among equity research firms.

Where relevant details were disclosed by the company and reflected in regulatory filings, Brophy’s transactions were executed on the dates reported and leave him with the direct share balance stated above.


Summary of facts:

  • March 10, 2026 - Brophy sold 785 shares at $204.1327 per share, totaling about $160,244.
  • March 9, 2026 - Brophy was issued 1,968 fully vested RSU shares.
  • Post-transactions direct ownership: 63,354 shares.
  • Q4 2025 revenue: $666 million versus expected $590.72 million.
  • Current share price: $196.61; 12-month return: +36%.
  • Canaccord Genuity: Buy rating, $285 price target; Morgan Stanley: Overweight rating, $250 price target (DCF-based).

Risks

  • Insider selling at a price higher than the current share price may be interpreted negatively by some market participants - this could affect investor sentiment in the diagnostics and healthcare sectors.
  • Divergent analyst price targets and model adjustments indicate uncertainty around valuation, which can increase volatility for the stock in equity markets.
  • Although the quarter beat revenue expectations, future performance or guidance was not detailed in these disclosures, leaving uncertainty about sustainability of growth across Natera’s testing businesses.

More from Insider Trading

nLIGHT CEO Disposes of $1.12M in Shares as Stock Nears 52-Week Peak Mar 12, 2026 Reddit CTO Completes $1.29M Share Sale, Exercises Options and Donates Large Block of Stock Mar 12, 2026 Symbotic Director Sells Nearly $191K in Class A Shares as Stock Climbs Mar 11, 2026 Symbotic Director Sells $95K in Class A Stock Amid Unit Redemptions; Q1 Results Show Mixed Signals Mar 11, 2026 General Atlantic-Led Group Acquires $50.56M in Alkami Technology Stock Mar 11, 2026